WSI Co

WSI Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of WSI Co (299170.KQ) as of Oct 16, 2026 is 3.92 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 4.83 B KRW — a change of -18.96% (lower).

EBITDA

3.92 BKRW

YoY

-18.96%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of WSI Co is 2025 3.92 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of WSI Co was 2024 4.83 B KRW. It decreases by -18.96% lower compared to the previous year.

The WSI Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-45.84 M KRW
Jan 1, 2019
-40.90 M KRW
Jan 1, 2020
5.38 B KRW
Jan 1, 2021
6.29 B KRW
Jan 1, 2022
4.12 B KRW
Jan 1, 2023
5.08 B KRW
Jan 1, 2024
4.83 B KRW
Jan 1, 2025
3.92 B KRW
The WSI Co EBITDA history
YEAREBITDAYoY
3.92 BKRW-18.96%
4.83 BKRW-4.80%
5.08 BKRW+23.32%
4.12 BKRW-34.55%
6.29 BKRW+16.81%
5.38 BKRW-13,262.43%
-40.90 MKRW-10.77%
-45.84 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WSI Co Stock analysis

What does WSI Co do? WSI Co Ltd is a South Korean company operating in the health care sector, headquartered in Seoul. The company went public on September 21, 2018, with a ticker symbol of 299170.KQ and ISIN KR7299170001. WSI Co Ltd manufactures medical devices and pharmaceutical products, focusing on specific therapeutic areas. The company distributes a topical hemostatic agent called Flosils. It also supplies endoscopes used in spinal surgery, anti-adhesion agents, and bone hemostatic agents. WSI Co Ltd's business activities are centered around medical devices and pharmaceuticals, with an emphasis on products that address hemostasis and surgical procedures. The company's website is https://wsi-healthcare.com/, where further information about its products and services may be found. As a publicly listed company, WSI Co Ltd operates within the South Korean financial market and serves customers primarily in the health care industry. The company's product portfolio includes both medical devices and pharmaceuticals, targeting specific clinical applications such as surgical hemostasis and spinal procedures. There is no indication of additional product lines or services beyond those mentioned in the source description. The company's operations are based in Seoul, South Korea, and it has been publicly traded since 2018. WSI Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WSI Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of WSI Co is 3.92 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of WSI Co changed from 4.83 B KRW to 3.92 B KRW, representing a -18.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) WSI Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s WSI Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — WSI Co

All Key Metrics — WSI Co